METAGENOMIC SEQUENCING FOR COMBINED DETECTION OF RNA AND DNA VIRUSES IN RESPIRATORY SAMPLES FROM PAEDIATRIC PATIENTS

3

4 Sander van Boheemen^{a*,^}, Anneloes L. van Rijn-Klink^{a*}, Nikos Pappas^b, Ellen C. Carbo^a,
5 Ruben H.P. Vorderman^b, Peter J. van 't Hof^b, Hailiang Mei^b, Eric C.J. Claas^a, Aloys C.M.
6 Kroes^{a\$}, Jutte J.C. de Vries^{a\$#}

7

8 ^aDepartment of Medical Microbiology,

9 Leiden University Medical Center, Leiden, The Netherlands

10 ^b Sequencing Analysis Support Core, Department of Biomedical Data Sciences,

11 Leiden University Medical Center, Leiden, The Netherlands

12

13 Running title: metagenomic sequencing for pan-viral detection

14

15 * These authors contributed equally to this work

16 \$ These authors contributed equally to this work

17 ^Present address: Sander van Boheemen, Department of clinical virology, Erasmus medical
18 Center, Rotterdam, The Netherlands

19 # Correspondence address: jjcdevries@lumc.nl

20

21 Keywords: metagenomics, mNGS, sequencing, pan-viral, virus, respiratory

22 **ABSTRACT**

23 Introduction

24 Viruses are the main cause of respiratory tract infections. Metagenomic next-generation
25 sequencing (mNGS) enables the unbiased detection of all potential pathogens in a clinical
26 sample, including variants and even unknown pathogens. To apply mNGS in viral
27 diagnostics, there is a need for sensitive and simultaneous detection of RNA and DNA
28 viruses. In this study, the performance of an in-house mNGS protocol for routine diagnostics
29 of viral respiratory infections, with single tube DNA and RNA sample-pre-treatment and
30 potential for automated pan-pathogen detection was studied.

31

32 Materials and Methods

33 The sequencing protocol and bioinformatics analysis was designed and optimized including
34 the optimal concentration of the spike-in internal controls equine arteritis virus (EAV) and
35 phocine-herpes virus-1 (PhHV-1). The whole genome of PhHV-1 was sequenced and added to
36 the NCBI database. Subsequently, the protocol was retrospectively validated using a selection
37 of 25 respiratory samples with in total 29 positive and 346 negative PCR results, previously
38 sent to the lab for routine diagnostics.

39

40 Results

41 The results demonstrated that our protocol using Illumina Nextseq 500 sequencing with 10
42 million reads showed high repeatability. The NCBI RefSeq database as opposed to the NCBI
43 nucleotide database led to enhanced specificity of virus classification. A correlation was
44 established between read counts and PCR cycle threshold value, demonstrating the semi-
45 quantitative nature of viral detection by mNGS. The results as obtained by mNGS appeared
46 concordant with PCR based diagnostics in 25 out of the 29 (86%) respiratory viruses positive
47 by PCR and in 315 of 346 (91%) PCR-negative results. Viral pathogens only detected by

48 mNGS, not present in the routine diagnostic workflow were influenza C, KI polyomavirus,
49 and cytomegalovirus.

50

51 Conclusions

52 Sensitivity and analytical specificity of this mNGS protocol was comparable with PCR and
53 higher when considering off-PCR target viral pathogens. All potential viral pathogens were
54 detected in one single test, while it simultaneously obtained detailed information on detected
55 viruses.

56

57 INTRODUCTION

58 Respiratory tract infections pose a great burden on public health, causing extensive morbidity
59 and mortality among patients worldwide [1-3]. The majority of acute respiratory infections is
60 caused by viruses, such as rhinovirus (RV), influenza (INF) A and B viruses,
61 metapneumovirus (MPV), and respiratory syncytial virus (RSV) [4]. However, in 20-62% of
62 the patients, no pathogen is detected [4-6]. This might be the result of diagnostic failures or
63 even infection by unknown pathogens, such as the Middle East respiratory syndrome
64 coronavirus (MERS-CoV), that was first recognized in 2012 [7].

65 Rapid identification of the respiratory pathogen is critical to determine downstream decision-
66 making such as isolation measures or treatment, including cessation of antibiotic therapy.
67 Current diagnostic amplification methods as real-time polymerase chain reaction (qPCR) are
68 very sensitive and specific, but are aiming at particular virus species or types. Genetic
69 diversity within the virus genome and the sheer number of potential pathogens in many
70 clinical conditions pose limitations to predefined primer and probe based approaches, leading
71 to false negative results [8]. These limitations, combined with the potential emergence of new
72 or unusual pathogens highlight the need for less restricted approaches that could improve the
73 diagnosis and subsequent outbreak management of infectious diseases.

74 Metagenomics relates to the study of the complete genomic content in a complex mixture of
75 (micro)organisms [9]. Unlike bacteria, viruses do not display a common gene in all virus
76 families, and therefore pan-virus detection relies on catch-all analytic methods.

77 Metagenomics or untargeted next-generation sequencing (mNGS) offers a culture and
78 nucleotide-sequence-independent method that eliminates the need to define the targets for
79 diagnosis beforehand. Besides primary detection, mNGS immediately offers additional
80 information, on virulence markers, epidemiology, genotyping, and evolution of pathogens [7,
81 10-12]. Furthermore, quantitative assessment of the presence of virus copies in the sample is
82 enabled by the number reads [8].

83 While original mNGS studies typically aim at analysis of (shifts in) population diversity of
 84 abundant DNA microbes, detection of viral pathogens in patient samples requires a different
 85 technical approach because of 1) the very low abundancy of viral pathogens (<1%) in clinical
 86 samples and 2) the requisite of detection of both DNA and RNA viruses. Hence, a low limit
 87 of detection for RNA and DNA in one single assay is essential for implementation of mNGS
 88 for routine pathogen detection in clinical diagnostic laboratories. Current viral mNGS
 89 protocols are optimized for either RNA or DNA detection [11, 13-15]. Consequently,
 90 detection of both RNA and DNA viruses requires parallel work-up of both RNA and DNA
 91 pre-treatment methods. Additionally, to increase the relative concentration of viral sequences,
 92 viral particle enrichment techniques are often applied [8, 12]. These techniques are laborious
 93 and not easily automated for routine clinical diagnostic use. Moreover, during enrichment
 94 directed at viral particles, intracellular viral nucleic acids as genomes and mRNAs are being
 95 discarded. Following sequencing, the bioinformatics classification and interpretation of the
 96 results remain a major challenge. Bioinformatic classifiers are often developed for usage in
 97 either microbiome studies or classification of high abundant reads whereas extensive
 98 validation for clinical diagnostic usage in settings of very low abundancy is very limited.
 99 After bioinformatics classification, the challenge remains to discriminate between viruses that
 100 play a role in aetiology and bona fide viruses [16]. Before mNGS might be considered in
 101 routine diagnostics, there is a need for critical evaluation and validation of every step in the
 102 procedure.

103 In this study, we evaluated a metagenomic protocol for NGS-based pathogen detection with
 104 sample pre-treatment for DNA and RNA in a single tube. The method was validated using a
 105 selection of 25 respiratory paediatric samples with in total 29 positive and 346 negative viral
 106 PCR results. The main study objective was to define a sensitive and specific method for
 107 mNGS to be used as a broad diagnostic tool for viral respiratory diseases with the potency for
 108 automated pan-pathogen detection.

MATERIAL AND METHODS

Sample selection

Twenty-five stored clinical respiratory samples (-80 °C) from paediatric patients, sent to the microbiological laboratory for routine viral diagnostics in 2016, were selected from the laboratory database (GLIMS, MIPS, Belgium) at the Leiden University Medical Center (LUMC). The selection was based on respiratory virus PCR test results: 21 out of the 25 samples had one or more positive PCR result, with a variety of respiratory viruses and a wide range of quantification cycle (Cq) values. The lab-developed real-time multiplex PCR method used was an updated version of the assay previously described by Loens et al [17]. The sample types represented the routine diagnostic samples from paediatric patients sent to our laboratory: predominantly nasopharyngeal washings (n=17), sputum (n=2) and broncho-alveolar lavages (BAL, n=2). The patient selection (age range 1.2 months – 15 years) represented the paediatric population with respiratory diagnostics in our university hospital in terms of (underlying) illness.

Sample pre-treatment

A sample pre-treatment protocol was designed with 1) potential for automation, 2) potential for pan-pathogen detection and 3) detection of intracellular viral nucleic acids. Consequently, any type of viral enrichment steps were excluded (filtration, centrifugation, nucleases, rRNA removal). Total nucleic acids (NA) were extracted directly from 200 µl of clinical material, using the MagNAPure 96 DNA and Viral NA Small Volume Kit (Roche Diagnostics, Almere, the Netherlands) with 100 µL output eluate.

Internal controls

Clinical material was spiked with equine arteritis virus (EAV) and phocine herpesvirus 1 (PhHV1, kindly provided by prof. dr. H.G.M. Niesters, the Netherlands) as internal controls for RNA and DNA virus detection respectively. To determine the optimal concentration of the internal controls a dilution series was added to a mix of two pooled influenza A positive throat swabs (Cq 25) (PhHV1/EAV 1:100,000 1:10,000 1:1,000 1:100). Concentration was based on the number of mNGS reads (Centrifuge output as well as BLAST) in order to serve as control [19].

Quality control

Before sequencing the DNA input concentration was measured with the Qubit (ThermoFisher Scientific, Waltham, USA), to determine whether there was sufficient DNA in the sample to obtain sequencing results. The range of DNA input for library preparation was 0.5 ng/μl for throat swabs (see reproducibility experiment) up to 300 ng/μl for bronchoalveolar lavages and sputa.

Fragmentation

To compare the effect of different DNA fragmentation techniques, ten samples were 1) chemically fragmented using zinc (10 min.) and 2) physically fragmented using sonication with the Bioruptor[®] pico (Diagenode, Seraing, Belgium, on/off time: 18/30s, 5 cycli) [20]. Three samples were also tested with the 3) high intensity settings of the Bioruptor[®] pico (on/off time: 30/40s, 14 cycli).

Library preparation

Libraries were constructed with 7µL extracted nucleic acids using the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® [21] using single, unique adaptors. This kit has been developed for transcriptome analyses. We made several adaptations to the manufacturers protocol in order to enable simultaneous detection of both DNA and RNA viruses: the following steps were omitted: Poly A mRNA capture isolation (Instruction manual NEB #E7420S/L, version 8.0, Chapter 1), rRNA depletion and DNase step (Chapter 2.1-2.4, 2.5B, 2.11A).

The size of fragments in the library was 300-700 bp. Adaptors were diluted 30 fold given the low RNA/DNA input and 21 PCR cycles were run post-adaptor ligation.

Nucleotide Sequence Analysis

Sequencing was performed on Illumina HiSeq 4000 and NextSeq 500 sequencing systems (Illumina, San Diego, CA, USA), obtaining 10 million 150 bp paired-end reads per sample.

Detection limit

To determine the detection limit of mNGS, serial dilutions (undiluted, 10^{-1} , 10^{-2} , 10^{-3} , 10^{-4}) of an influenza A positive sample was tested with both lab developed real-time PCR and mNGS.

Repeatability (within run precision)

To determine the reproducibility of metagenomic sequencing an influenza A positive clinical sample (throat swab) was tested in quadruple. This sample was divided into separate aliquots, nucleic acids were extracted, library preparation and subsequent sequence analysis on the Illumina HiSeq 4000 was performed in one run.

181

182 **Bioinformatics: taxonomic classification**

183 All FASTQ files were processed using the BIOPET Gears pipeline version 0.9.0 developed at
 184 the LUMC [22]. This pipeline performs FASTQ pre-processing (including quality control,
 185 quality trimming and adapter clipping) and taxonomic classification of sequencing reads. In
 186 this project, FastQC version 0.11.2 [23] was used for checking the quality of the raw reads.
 187 Low quality read trimming was done using Sickle [24] version 1.33 with default settings.
 188 Adapter clipping was performed using Cutadapt [25] version 1.10 with default settings.
 189 Taxonomic classification of reads was performed with Centrifuge [26] version 1.0.1-beta.
 190 The pre-built NT index, which contains all sequences from NCBI's nucleotide database,
 191 provided by the Centrifuge developers was used
 192 (<ftp://ftp.ccb.jhu.edu/pub/infphilo/centrifuge/data/nt.tar.gz>) as the reference database.

193 In addition, a customized reference centrifuge index with sequence information obtained
 194 from the NCBI's RefSeq [27] (accessed November 2017) database was built. RefSeq
 195 genomic sequences for the domains of bacteria, viruses, archaea, fungi, protozoa, as well as
 196 the human reference, along with the taxonomy identifiers, were downloaded with the
 197 Centrifuge-download utility and were used as input for centrifuge-build.

198 Centrifuge settings were evaluated to increase the sensitivity and specificity. The default
 199 setting, with which a read can be assigned to up to five different taxonomic categories, was
 200 compared to one unique assignment per read [26] where a read is assigned to a single
 201 taxonomic category, corresponding to the lowest common ancestor of all matching species.

202 Kraken-style reports with taxonomical information were produced by the Centrifuge-kreport
 203 utility for all (default) options. Both unique and non-unique assignments can be reported, and
 204 these settings were compared. The resulting tree-like structured, Kraken-style reports were
 205 visualized with Krona [28] version 2.0.

In silico simulated EAV reads were analysed in different databases (NCBI nucleotide vs RefSeq), classification algorithms (max 5 labels per sequence, vs unique (common ancestor)) and reporting (non-unique vs unique) to determine the most sensitive and specific bioinformatic analyses using Centrifuge.

To determine the amount of reads needed, results of 1 and 10 million reads were compared. 1 million reads were randomly selected of the 10 million reads of one FASTQ file and analysed.

Bioinformatics: assembly of PhHV1 sequences

Assembly of PhHV1 was done using the bowtie virus-assembly pipeline 0.1 [29]. The QC part of the bowtie pipeline determines which adapters need to be clipped by using FastQC version 0.11.7 [23] and cutadapt version 1.16 [25], with minimum length setting “1”. The resulting reads were downsampled within bowtie to 250 000 reads using seqtk 1.2 [30] after which SPADes version 3.11.1 [31] was run to get the first proposed genome contigs.

To retrieve longer assembly contigs a reiterative assembly approach was used by processing the proposed contigs by the bowtie reAssembly pipeline 0.1. This preassembly pipeline aligns reads to contigs of a previous assembly, then selects the aligned reads, downsamples them and runs a new assembly using SPADes. Subtools used for this consisted of BWA 0.7.17 [32] for indexing and mapping, SAMtools 1.6 [33] for creating bam files, SAMtools view (version 1.7) for filtering out unmapped reads using the setting “-G 12”, Picard SamToFastq (version 2.18.4) and seqtk for creating fastq files with 250 000 reads. The contigs from the reAssembly pipeline were then processed for a second using SPADes, with setting the ‘cov-cutoff’ to 5. The resulting contigs were then processed with the reAssembly pipeline for the third and last time setting the ‘cov-cutoff’ in SPADes to 20.

The contigs from the last reAssembly step were then run against the blast NT database using blastn 2.7.1 [19] Out of 23 contigs only 5 contigs, that showed the lowest % in identity matches with any other possible non herpes virus species, were selected. The final 5 contigs contained sequence lengths of 97893, 8170 3710, 3294 and 1279 nucleotides, the average coverage was 206, 131, 211, 285 and 154, respectively. These five contigs were published as partial genome under accession number (NCBI accession number: MH509440)

Retrospective validation

Sensitivity and specificity of the metagenomic NGS procedure was compared with the lab developed multiplex qPCR [17] using a selection of 21 samples positive for at least one respiratory PCR target and 4 negative samples.. The routine multiplex PCR panel consisted of 15 respiratory target pathogens: influenza virus A/ B, respiratory syncytial virus (RSV), metapneumovirus (MPV), adenovirus (ADV), human bocavirus (HBoV), parainfluenza viruses (PIV) 1/ 2/ 3/ 4, rhinovirus (RV), and the coronaviruses HKU1, NL63, 227E and OC43. Thus, in total 375 PCR results were available (15 targets x 25 samples) of which 29 PCR positive and 346 PCR negative for comparison with mNGS. Validation samples were tested with mNGS, using the total NA extraction protocol, the adapted NEBNext library preparation protocol, and sequencing 10 million reads on an Illumina NextSeq 500. Bioinformatics analyses was performed using Centrifuge with the RefSeq database and unique assignment of sequence reads.

Ethical approval of patient studies

The study design was approved by the medical ethics review committee of the Leiden University Medical Center.

RESULTS

Internal controls

Serial dilutions of EAV and PhHV1 were added to an influenza A PCR positive sample. Serial dilution 1:10,000 detected EAV with a substantial read count in the presence of a viral infection and without a significant decline in target virus family reads (Table 1). Based on these results we determined the concentration of internal controls for further experiments. The EAV Cq value of the dilutions correlated with the number of EAV reads from both BLAST alignment and the Centrifuge analysis (Figure 1). Since the NCBI database was lacking a complete PhHV1 genome sequence, PhHV1 was sequenced and based on the gained sequence reads the genome was build using SPAdes [31]. The proposed almost complete genome of PhHV1 was added to the NCBI genbank database (submission ID 2124975, GenBank MH509440, release date 4 Dec 2018) and used for BLAST alignment.

Fragmentation

The comparison of fragmentation methods for a selection of the samples with relevant target reads, is shown in Figure 2. Root reads were comparable among the three protocols. The protocol with fragmentation with Zinc had higher yield in target virus reads for all RNA viruses tested and adenovirus.

Index hopping

Sequence analysis by Illumina HiSeq 4000 with single, unique indexes resulted in HRV-C sequences (22-159 reads), in all samples run on the same lane, in contrast to samples run on

another lane. Comparison of HRV-C sequences between these samples resulted in an exact match. Retesting of these samples with Illumina Nextseq 500 resulted in disappearance of HRV reads in the samples, with the exception of a few HRV PCR positive samples (Figure 3). Combined, this was highly suggestive for index hopping at the Illumina HiSeq 4000 [34].

Detection limit

The detection limit, deduced from serial dilutions of EAV (Figure 1) and influenza A (Figure 4) was comparable with a real time PCR C_q value of approximately 35.

Repeatability: within run precision

The mNGS results of an influenza A positive sample tested in quadruple could be reproduced with only minor differences (table 1): coefficient of variation of 1.2%: 0.05 log SD/ 4.0 log average.

Bioinformatics: taxonomic classification

The Centrifuge default settings, with the NCBI nucleotide database and maximum 5 labels per sequence, resulted in various spurious classifications (Figure 5), for example Lassa virus (Figure 6), evidently highly unlikely to be present in patient samples from the Netherlands with respiratory complaints. The specificity could be increased by using the NCBI RefSeq database instead of the nucleotide database. The classification was further improved by changing the Centrifuge tool settings to limit the assignment of homologous reads to the lowest common ancestor (maximum 1 label per sequence). Classification with maximum 5 labels per read resulted in two different outcomes using the report with all mappings and the

report with unique mappings, with the latter missing the reads assigned to multiple organisms.

Comparison of classification using these different settings shows the highest sensitivity and specificity using the RefSeq database with one label (lowest common ancestor) assignment, both with in silico prepared datasets containing solely EAV sequence fragments (Figure 5) and with clinical datasets (with highly abundant background) (Figure 6).

To determine the effect of the total number of sequencing reads obtained per sample on sensitivity, one million and 10 million reads were compared by means of in silico analysis (Table 2).

Retrospective validation

Clinical sensitivity based on PCR target pathogens

The sample collection consisted of 21 clinical specimens positive for at least one of the following PCR target viruses: rhinovirus, influenza A&B, parainfluenza 1 &4 (PIV), metapneumovirus, respiratory syncytial virus, coronaviruses NL63 and HKU1 (CoV), human bocavirus (hBoV), and adenovirus (ADV). Fourteen samples were positive for one virus, six samples for two and one sample for three viruses with the lab-developed respiratory multiplex qPCR. Cq values ranged from Cq 17 to Cq 35, with a median of 23.

With mNGS 25 of the 29 viruses demonstrated in routine diagnostics were detected (Table 3), resulting in a sensitivity of 86% for PCR targets. If a cut-off of 15 reads was handled, sensitivity declined to 67% (Table 4).

mNGS target read count showed a correlation with the Cq values of the qPCR (Figure 7).

Detection of additional viral pathogens by mNGS: off-PCR target viruses

Next to the viral pathogens tested by PCR, mNGS also detected other pathogenic viruses, indicating additional viral sequences uncovered by mNGS but not included in the routine diagnostics, with influenza C virus being the most prominent. A high amount, 4800 reads, of influenza virus C reads (C/Ann Arbor/1/50) (88% of all viral reads and 0.02 of the total reads) was found in one sample. Other potential respiratory pathogens detected by mNGS and not included in PCR analysis were KI polyomavirus (2 samples: 159 and 30 reads respectively), cytomegalovirus (human betaherpesvirus 5) (1704 and 132 reads). All of these viruses are not included routinely in the diagnostic multiplex qPCRs.

Internal controls

The spiked-in internal controls were detected by mNGS in all samples. EAV sequence reads ranged from 18-34660 (median 538) and herpesviridae reads as indicator of PhHV1 ranged from 1-1707 (median 23).

Analytical specificity based on PCR target viruses

In total 25 paediatric respiratory samples were available for analysis of analytical specificity of mNGS: 4 samples were negative for all 15 viral pathogens in the multiplex PCR panel (influenza A/B, RSV, HMPV, ADV, HBoV, PIV1/2/3/4, RV, HKU1, NL63, 227E, OC43) and 21 samples were negative for 12-14 of these PCR target pathogens.

Out of in total 346 negative target PCR results of these 25 samples, 315 results corresponded with the finding of 0 target specific reads by mNGS. If a cut-off of 15 reads was used 343 of the 346 negative PCR targets were negative with mNGS. The 3 samples positive by mNGS and negative by PCR were human parainfluenzavirus 1 (27 reads), 3 (31 reads), and 4 (27 reads). Though no conclusive proof for neither true positive or false mNGS results could be

found, specificity of mNGS was 91% (315/346) when encountering all reads and $\geq 99\%$ (343/346) with a 15 reads cut-off (Table 6).

Drug resistance data

Using the sequence data we identified several mutations on the genome of two clinical samples tested positive for influenza A virus. None of these mutations conferred resistance to either oseltamivir or zanamivir. For the positions where resistance associated mutations occur, amino acids I117, E119, D198, I222, H274, R292, N294 and I314 showed susceptibility to oseltamivir and V116, R118, E119, Q136, D151, R152, R224, E276, R292 and R371 revealed susceptibility to zanamivir [35, 36].

DISCUSSION

Metagenomic sequencing has not yet been implemented as routine diagnostic tool in clinical diagnostics of viral infections. Such application would require the careful definition and validation of several parameters to enable the accurate assessment of a clinical sample with regard to the presence or absence of a pathogen, in order to fulfil current accreditation guidelines. For this purpose, this study has initiated the optimization of several steps throughout the pre- and post-sequencing workflow, which are considered essential for sensitive and specific mNGS based virus detection. Many virus discovery or virus diagnostic protocols have focussed on the enrichment of viral particles [37] with the intention to increase the relative amount of virus reads. However, these methods are laborious and intrinsically exclude viral nucleic acid located in host cells. The current protocol enabled high throughput sample pre-treatment by means of automated NA extraction and without depletion of bacterial nor human genome, with potential for pan-pathogen detection. Several adaptations in the bioinformatic script resulted in more accurate classification output reporting.

The addition of an internal control to a PCR reaction is widely used as a quality control of a qPCR [38]. While the addition of internal controls in mNGS is not yet an accepted standard procedure, we employed EAV and PhHV1 as RNA and DNA controls, respectively, as for diagnostic application such precautions are required. The amount of internal control reads and target virus reads have been reported to be dependent of the amount of background reads (negative correlation) [39]. In our protocol, the internal controls were used as qualitative controls but may be used as indicator of the amount of background. Since the NCBI database was lacking a complete PhHV1 genome, the Centrifuge index building and classification was limited to classification on a higher taxonomic rank. In order to achieve classification of PhHV1 at species level, the whole genome of PhHV1 was sequenced, and based on the gained sequence reads the genome was built [31]. The proposed almost complete genome of PhHV1 was added to the NCBI GenBank database.

Sensitivity of the mNGS protocol was 86% (25/29) based on PCR target viruses. Four, all RNA viruses, that were not recovered by mNGS had high Cq values, over 31, i.e. a relatively low viral load. This may be a drawback of the retrospective nature of this clinical evaluation as RNA viruses may be degraded due to storage and freeze-thaw steps, resulting in lower sensitivity of mNGS. A correlation was found between read counts and PCR Cq value, demonstrating the quantitative nature of viral detection by mNGS. Discrepancies between the Cq values and the number of mNGS reads may be explained by 1) unrepresentative Cq values, e.g. by primer mismatch for highly divergent viruses like rhino/enteroviruses and 2) differences in sensitivity of mNGS for several groups of viruses, as has been reported by others [42]. Additionally, several viral pathogens were detected that were not targeted by the routine PCR assays, including influenza C virus, which is typical of the unbiased nature of the method. In addition, though not within the scope of this study, bacterial pathogens, including *Bordetella pertussis* (qPCR positive), were also detected. In the current study only viruses were targeted since these could be well compared to qPCR results, bacterial targets remain to be studied in clinical sample types more suitable for bacterial detection than nasopharyngeal washings. The analytical specificity of mNGS appeared to be high, especially with a cut-off of 15 reads. However, the clinical specificity, the relevance of the lower read numbers, still needs further investigation in clinical studies.

Sequencing using Illumina HiSeq 4000 chemistry resulted in frequent false positive rhinovirus reads in numerous samples. This problem could be attributed to ‘index hopping’ (index miss-assignment) as earlier described [34]. Although the percentage of reads which contributed to the index hopping was very low, this is critical for clinical viral diagnostics, as this is aimed specifically at low abundance targets [34, 40].

Bioinformatics classification of metagenomic sequence data with the pipeline Centrifuge required identification of the optimal parameters in order to minimize miss- and unclassified reads. Default settings of this pipeline resulted in higher rates of both false positive and false negative results. The nucleotide database includes a wide variety of unannotated viral

sequences, such as partial sequences and (chimeric) constructs, in contrast to the curated and well-annotated sequences in the NCBI Refseq database, which resulted in a higher specificity. In addition to the database, settings for the assignment algorithm were adapted as well. The assignment settings were adjusted to unique assignment in the case of homology to the lowest common ancestor. This modification resulted in higher sensitivity and specificity than the default settings, however the ability to further subtyping diminished. This is likely to be attributed to the limited representation/availability of strain types within the RefSeq database. In consequence, this leads to a more accurate estimation of the common ancestor for particular viruses, but limited typing results in case of highly variable ones. To obtain optimal typing results, additional annotated sequences may be added or a new database should be build, with a high variety of well-defined and frequently updated virus strain types.

To conclude, this study contributes to the increasing evidence that metagenomic NGS can effectively be used for a wide variety of diagnostic assays in virology, such as unbiased virus detection, resistance mutations, virulence markers, and epidemiology, as shown by the ability to detect SNPs in influenza virus.

These findings support the feasibility of moving this promising field forward to a role in the routine detection of pathogens by the use of mNGS. Further optimization should include the parallel evaluation of adult samples, the inclusion of additional annotated strain sequences to the database, and further elaboration of the classification algorithm and reporting for clinical diagnostics. The importance of both negative non-template control samples [41] and healthy control cases may support the critical discrimination of contaminants and viral ‘colonization’ from clinically relevant pathogens.

CONCLUSIONS

Optimal sample preparation and bioinformatics analysis are essential for sensitive and specific mNGS based virus detection.

Using a high-throughput genome extraction method without viral enrichment, both RNA and DNA viruses could be detected with a sensitivity comparable to PCR.

Using mNGS, all potential pathogens can be detected in one single test, while simultaneously obtaining additional detailed information on detected viruses. Interpretation of clinical relevance is an important issue but essentially not different from the use of PCR based assays and supported by the available information on typing and relative quantities. These findings support the feasibility of a role of mNGS in the routine detection of pathogens.

ACKNOWLEDGEMENTS

We thank our project partners Floyd Wittink, Wouter Suring (Hogeschool Leiden), Danny Duijsings (BaseClear) and Christiaan Henkel (Leiden University). We also like to thank thank Tom Vreeswijk, Lopje Höcker and Mario van Bussel (KML, LUMC) for help with the pre-sequencing experiments and Jeroen Laros (Human Genetics, LUMC) for help with the bioinformatics.

AUTHOR CONTRIBUTIONS

SB, ALR, ECJC, ACMK, and JJC participated in the study design. SB performed the pre-library preparation experiments. SB, NP, ECC, RHPV, PH, and HM carried out bioinformatic analyses. SB, ALR and ECC analyzed the data. SB and ALR wrote the first version of the manuscript. All authors contributed and revised the manuscript and approved the final manuscript.

DISCLOSURE DECLARATION

This research is partially funded by GENERADE Centre of Expertise Genomics in Leiden.

465 Competing interests: none declared.

466

467 DATA ACCESS

468 The raw datasets of this study are not publicly made available given the confidential character
469 of human sequences.

470

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY *et al*: **Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.** *Lancet (London, England)* 2012, **380**(9859):2095-2128.
2. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moisi JC, Roca A *et al*: **Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis.** *Lancet (London, England)* 2013, **381**(9875):1380-1390.
3. Bates M, Mudenda V, Mwaba P, Zumla A: **Deaths due to respiratory tract infections in Africa: a review of autopsy studies.** *Current opinion in pulmonary medicine* 2013, **19**(3):229-237.
4. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM *et al*: **Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.** *N Engl J Med* 2015, **373**(5):415-427.
5. Heikkinen T, Jarvinen A: **The common cold.** *Lancet (London, England)* 2003, **361**(9351):51-59.
6. Ieven M, Coenen S, Loens K, Lammens C, Coenjaerts F, Vanderstraeten A, Henriques-Normark B, Crook D, Huygen K, Butler CC *et al*: **Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11**

- 494 **European countries.** *Clinical microbiology and infection : the official publication of*
495 *the European Society of Clinical Microbiology and Infectious Diseases* 2018.
- 496 7. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA: **Isolation**
497 **of a novel coronavirus from a man with pneumonia in Saudi Arabia.** *N Engl J*
498 *Med* 2012, **367**(19):1814-1820.
- 499 8. Prachayangprecha S, Schapendonk CM, Koopmans MP, Osterhaus AD, Schurch AC,
500 Pas SD, van der Eijk AA, Poovorawan Y, Haagmans BL, Smits SL: **Exploring the**
501 **potential of next-generation sequencing in detection of respiratory viruses.**
502 *Journal of clinical microbiology* 2014, **52**(10):3722-3730.
- 503 9. Wooley JC, Godzik A, Friedberg I: **A primer on metagenomics.** *PLoS*
504 *computational biology* 2010, **6**(2):e1000667.
- 505 10. Hoffmann B, Scheuch M, Hoper D, Jungblut R, Holsteg M, Schirrmeyer H,
506 Eschbaumer M, Goller KV, Wernike K, Fischer M *et al*: **Novel orthobunyavirus in**
507 **Cattle, Europe, 2011.** *Emerging infectious diseases* 2012, **18**(3):469-472.
- 508 11. Mongkolrattanothai K, Naccache SN, Bender JM, Samayoa E, Pham E, Yu G, Dien
509 Bard J, Miller S, Aldrovandi G, Chiu CY: **Neurobrucellosis: Unexpected Answer**
510 **From Metagenomic Next-Generation Sequencing.** *Journal of the Pediatric*
511 *Infectious Diseases Society* 2017, **6**(4):393-398.
- 512 12. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM,
513 Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ *et al*: **Genomic**
514 **characterization of a newly discovered coronavirus associated with acute**
515 **respiratory distress syndrome in humans.** *mBio* 2012, **3**(6).

- 516 13. Kohl C, Brinkmann A, Dabrowski PW, Radonic A, Nitsche A, Kurth A: **Protocol for**
517 **metagenomic virus detection in clinical specimens.** *Emerging infectious diseases*
518 2015, **21**(1):48-57.
- 519 14. Parker J, Chen J: **Application of next generation sequencing for the detection of**
520 **human viral pathogens in clinical specimens.** *Journal of clinical virology : the*
521 *official publication of the Pan American Society for Clinical Virology* 2017, **86**:20-26.
- 522 15. Zou X, Tang G, Zhao X, Huang Y, Chen T, Lei M, Chen W, Yang L, Zhu W, Zhuang
523 L *et al*: **Simultaneous virus identification and characterization of severe**
524 **unexplained pneumonia cases using a metagenomics sequencing technique.**
525 *Science China Life sciences* 2017, **60**(3):279-286.
- 526 16. Wylie KM, Mihindukulasuriya KA, Sodergren E, Weinstock GM, Storch GA:
527 **Sequence analysis of the human virome in febrile and afebrile children.** *PloS one*
528 2012, **7**(6):e27735.
- 529 17. Loens K, van Loon AM, Coenjaerts F, van Aarle Y, Goossens H, Wallace P, Claas
530 EJ, Ieven M: **Performance of different mono- and multiplex nucleic acid**
531 **amplification tests on a multipathogen external quality assessment panel.** *Journal*
532 *of clinical microbiology* 2012, **50**(3):977-987.
- 533 18. Welsh J, McClelland M: **Fingerprinting genomes using PCR with arbitrary**
534 **primers.** *Nucleic acids research* 1990, **18**(24):7213-7218.
- 535 19. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: **Basic local alignment**
536 **search tool.** *Journal of molecular biology* 1990, **215**(3):403-410.

- 537 20. Wery M, Describes M, Thermes C, Gautheret D, Morillon A: **Zinc-mediated RNA**
538 **fragmentation allows robust transcript reassembly upon whole transcriptome**
539 **RNA-Seq. *Methods (San Diego, Calif)* 2013, 63(1):25-31.**
- 540 21. **New England BioLabs Inc.** [[https://www.neb.com/products/e7420-nebnext-ultra-](https://www.neb.com/products/e7420-nebnext-ultra-directional-rna-library-prep-kit-for-illumina#Product%20Information)
541 [directional-rna-library-prep-kit-for-illumina#Product%20Information](https://www.neb.com/products/e7420-nebnext-ultra-directional-rna-library-prep-kit-for-illumina#Product%20Information)] Version 8.0.
- 542 22. [<http://biopet-docs.readthedocs.io/en/stable/>]
- 543 23. [<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>]
- 544 24. Joshi NA, Fass JN: **Sickle: A sliding-window, adaptive, quality-based trimming**
545 **tool for FastQ files.** 2011.
- 546 25. Martin M: **Cutadapt removes adapter sequences from high-throughput**
547 **sequencing reads.** *EMBnetjournal* 2011, **17**(10).
- 548 26. Kim D, Song L, Breitwieser FP, Salzberg SL: **Centrifuge: rapid and sensitive**
549 **classification of metagenomic sequences.** *Genome research* 2016, **26**(12):1721-
550 1729.
- 551 27. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B,
552 Robbertse B, Smith-White B, Ako-Adjei D *et al*: **Reference sequence (RefSeq)**
553 **database at NCBI: current status, taxonomic expansion, and functional**
554 **annotation.** *Nucleic acids research* 2016, **44**(D1):D733-745.
- 555 28. Ondov BD, Bergman NH, Phillippy AM: **Interactive metagenomic visualization in**
556 **a Web browser.** *BMC bioinformatics* 2011, **12**:385.

- 557 29. <https://github.com/biowdl/virus-assembly>
- 558 30. <https://github.com/lh3/seqtk>
- 559 31. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM,
560 Nikolenko SI, Pham S, Prjibelski AD *et al*: **SPAdes: a new genome assembly**
561 **algorithm and its applications to single-cell sequencing**. *Journal of computational*
562 *biology : a journal of computational molecular cell biology* 2012, **19**(5):455-477.
- 563 32. Li H: **Aligning sequence reads, clone sequences and assembly contigs with BWA-**
564 **MEM**, vol. 1303; 2013.
- 565 33. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
566 Durbin R: **The Sequence Alignment/Map format and SAMtools**. *Bioinformatics*
567 (*Oxford, England*) 2009, **25**(16):2078-2079.
- 568 34. Sinha R, Stanley G, Gulati GS, Ezran C, Travaglini KJ, Wei E, Chan CKF, Nabhan
569 AN, Su T, Morganti RM *et al*: **Index Switching Causes “Spreading-Of-Signal”**
570 **Among Multiplexed Samples In Illumina HiSeq 4000 DNA Sequencing**. *bioRxiv*
571 2017.
- 572 35. Orozovic G, Orozovic K, Lennerstrand J, Olsen B: **Detection of resistance**
573 **mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses**
574 **isolated from wild birds**. *PloS one* 2011, **6**(1):e16028.
- 575 36. Hsieh NH. Assessing the oseltamivir-induced resistance risk and implications for
576 influenza infection control strategies. *Infect Drug Resist*. 2017;10:215-226

- 577 37. Hasan MR, Rawat A, Tang P, Jithesh PV, Thomas E, Tan R, Tilley P: **Depletion of**
578 **Human DNA in Spiked Clinical Specimens for Improvement of Sensitivity of**
579 **Pathogen Detection by Next-Generation Sequencing.** *Journal of clinical*
580 *microbiology* 2016, **54**(4):919-927.
- 581 38. Ninove L, Nougairede A, Gazin C, Thirion L, Delogu I, Zandotti C, Charrel RN, De
582 Lamballerie X: **RNA and DNA bacteriophages as molecular diagnosis controls in**
583 **clinical virology: a comprehensive study of more than 45,000 routine PCR tests.**
584 *PloS one* 2011, **6**(2):e16142.
- 585 39. Schlager R, Chiu CY, Miller S, Procop GW, Weinstock G: **Validation of**
586 **Metagenomic Next-Generation Sequencing Tests for Universal Pathogen**
587 **Detection.** *Archives of pathology & laboratory medicine* 2017, **141**(6):776-786.
- 588 40. van der Valk T, Vezzi F, Ormestad M, Dalen L, Guschanski K: **Estimating the rate**
589 **of index hopping on the Illumina HiSeq X platform.** *bioRxiv* 2018.
- 590 41. Naccache SN, Hackett J, Jr., Delwart EL, Chiu CY: **Concerns over the origin of**
591 **NIH-CQV, a novel virus discovered in Chinese patients with seronegative**
592 **hepatitis.** *Proceedings of the National Academy of Sciences of the United States of*
593 *America* 2014, **111**(11):E976.
- 594 42. Bal A, Pichon M, Picard C, Casalegno JS, Valette M, Schuffenecker I, Billard L,
595 Vallet S, Vilchez G, Cheynet V, Oriol G, Trouillet-Assant S, Gillet Y, Lina B,
596 Brengel-Pesce K, Morfin F, Josset L: **Quality control implementation for universal**
597 **characterization of DNA and RNA viruses in clinical respiratory samples using**
598 **single metagenomics next-generation sequencing workflow.** *BMC Infect Dis* 2018:
599 18(1):537

TABLES

Table 1. Internal controls EAV/PhHV-1: serial dilutions against a clinical sample background and within-run precision (INFA)

Sample nr	INFA Cq	EAV Cq	PhHV-1 Cq	INFA reads centrifuge	INFA reads BWA	EAV reads Centrifuge	EAV reads BWA	PhHV-1 reads BWA
1	24.79	30.85	32.55	8843 (3.9 log)	9805	9	72	3302
2	24.76	28.45	30.33	11011 (4.0 log)	12570	49	417	3773
3	24.67	24.91	26.83	8525 (3.9 log)	9260	520	5130	6664
4	24.52	21.59	23.52	10010 (4.0 log)	11384	5634	54366	19984

Abbreviations: nr: number, Cq: quantification cycle value, INFA: influenza A, EAV: equine arteritis virus, PhHV-1 phocine herpesvirus 1.

PhHV-1 reads were based on BWA alignment, since the PhHV-1 genome was lacking in the NCBI database

Table 2. Comparison of analysis of 1 million vs 10 million reads.

virus	virusfamily	Cq value	10 million reads				1 million reads			
			Root reads	virus family reads	% root	% viral	Root reads	virus family reads	% root	% viral
RV	Picornaviridae	37.7	8203894	5290	0.06	84.37	822218	527	0.07	86.11
PIV4	Paramyxoviridae	24.9	10886798	3965	0.04	41.90	1088067	369	0.08	40.73
CMV	Herpesviridae	34.5	15889428	806	00.01	10.88	1588922	82	0.04	11.87
ADV	Adenoviridae	30.2	11146488	0	0	0	1115135	0	0.03	0
RSV	Paramyxoviridae	27.3	10191995	2287	0.02	53.29	1019415	253	0.04	59.25
INFB	Orthomyxoviridae	30	8535672	804	0.01	48.67	853149	75	0.02	46.58
NL63	Coronaviridae	36.2	10386928	0	0	0	1038469	0	0.02	0
INFA	Orthomyxoviridae	27.5	10981601	12539	0.11	70.28	1097872	1276	0.17	69.84
MPV	Paramyxoviridae	34.1	12972626	3	0	0.10	1297151	0	0.02	0
HBOV	Parvoviridae	32.2	11819805	0	0	0	1181738	0	0	0
RV	Picornaviridae	23.1	11819805	50034	0.42	84.27	1183738	4912	0.49	84.25

Abbreviations: Cq: quantification cycle value, % root: percentage of total root reads, % viral: percentage of all viral reads , RV: rhinovirus,

PIV4: parainfluenza 4, CMV: cytomegalovirus, ADV: adenovirus, RSV: respiratory syncytial virus, INF: influenza, NL63: coronavirus NL63,

MPV: metapneumovirus, hBoV: human bocavirus

Table 3. Detection of qPCR viruses positive respiratory samples with mNGS

Routine diagnostics					Metagenomic NGS					
sample nr.	material	PCR positive	Cq values	Root reads	Virus genus	reads	% root	Virus species	reads	% root
1	np wash	RV	30,7	12031393	Enterovirus	0		Rhinovirus	0	
		PIV1	17,1		Respirovirus	106218	0.9	Human respirovirus 1	106153	0.9
		ADV	33,6		Mastadenovirus	2	0.00002	Human mastadenovirus C	2	0.00002
2	np wash	MPV	24	12628716	Metapneumovirus	288	0.002	Human metapneumovirus	288	0.002
3	BAL	NL63	24,4	10928011	Alphacoronavirus	7385	0.07	Human coronavirus NL63	7385	0.07
		HKU1	28,2		Betacoronavirus	4	0.00004	human coronavirus HKU1	4	0.00004
4	sputum	RV	32	9906552	Enterovirus	1349	0.01	Rhinovirus B14	836	0.008
5	np wash	INFA	22,2	12923454	Influenzavirus A	2619	0.02	Influenza A virus	2619	0.02
6	np wash	MPV	33,4	8950930	Metapneumovirus	4	0.00004	Human metapneumovirus	4	0.00004
		ADV	19,3		Mastadenovirus	685	0.004	Human mastadenovirus C	397	0.004
7	sputum	PIV4	21	13045439	Rubulavirus	15066	0.1	Human parainfluenza virus 4a	15066	0.1
8	np wash	HBoV	22,3	21601343	Bocaparvovirus	8	0.00004	Human bocavirus	8	0.00004
9	np wash	MPV	22,2	14159037	Metapneumovirus	352	0.002	Human metapneumovirus	326	0.002
10	np wash	INFB	16,5	9868792	Influenzavirus B	7091	0.07	Influenza B	7091	0.07
11	np wash	RV	25,4	14291308	Enterovirus	4	0.00003	Rhinovirus A	4	0.00003
		RSV	30,7		Orthopneumovirus/RSV	72	0.0005	Respiratory syncytial virus	1	0.00000
12	np wash	INFB	21,4	14580692	Influenzavirus B	5742	0.04	Influenza B virus	5742	0.04
13	np wash	RSV	17,8	19653579	Orthopneumovirus/RSV	93260	0.5	Respiratory syncytial virus	92504	0.5
14	np wash	RV	34,4	13659957	Enterovirus	0		Rhinovirus	0	
		INFB	22,6		Influenzavirus B	136358	1	Influenza B virus	136358	1

15	BAL	INFB	34,8	9294798	Influenzavirus	0		Influenza virus	0	
		HBoV	34,1		Bocaparvovirus	0		Bocavirus	0	
16	np wash	HKU1	24,3	12998763	Betacoronavirus	2086	0.02	Human coronavirus HKU1	2086	0.02
17	np wash	RV	16,8	12377898	Enterovirus	1457	0.01	Rhinovirus A	1157	0.009
18	np wash	RV	27,4	10951756	Enterovirus	1	0.000009	Rhinovirus B14	1	0.000009
		HBoV	19		Bocaparvovirus	610	0.006	Human bocavirus	610	0.006
19	np wash	INFA	22,1	15885048	Influenzavirus A	1425	0.009	Influenza A virus	1425	0.009
20	np wash	RSV	17,2	14168817	Orthopneumovirus/RSV	66711	0.05	Respiratory syncytial virus	241	0.002
21	np wash	RV	17,7	1358038	Enterovirus	2539	0.02	Rhinovirus A	2539	0.02

Abbreviations: NGS: next generation sequencing, nr: number, Cq: quantification cycle value, % root: percentage of total root reads, Np wash: nasopharyngeal wash, BAL: bronchoalveolar lavage, RV: rhinovirus, PIV parainfluenza, ADV: adenovirus, MPV: metapneumovirus, NL63: coronavirus NL63, HKU1: coronavirus HKU1, INF: influenza, hBoV: human bocavirus, RSV: respiratory syncytial virus

Table 4. Sensitivity and specificity of the mNGS protocol tested, based on PCR target virus, and different cut-off levels for defining a positive result.

	All reads	≥15 reads	≥50 reads
Sensitivity	86	67	67
Specificity	91	99	100

Figure 1. Correlation of Cq value and the number of EAV reads (serial dilutions).

Figure 2. Comparison of fragmentation methods on target reads (species level, log scale).

*Not tested with Bioruptor setting high intensity.

Figure 3. Decline in index hopping (percentages Rhinovirus C of root reads) with Illumina NextSeq 500 as compared to HiSeq 4000. Each line represents one sample.

Figure 4. Serial dilutions of an influenza A positive clinical sample.

Figure 5. Analysis of in silico simulated EAV reads with the different bioinformatic settings of the Centrifuge pipeline.

Figure 6. Spurious Lassa virus reads with the NCBI Nucleotide (NT) database versus the RefSeq database. k5; up to 5 labels per sequence.

Figure 7. Semi-quantification of the mNGS assay for target virus detection in clinical samples with qPCR confirmed human respiratory viruses.